Survival analyses (Cox regression) revealed that relative to placebo, all active treatments significantly increased the number of days to relapse using both the unadjusted (p < .05) as well as the Bonferroni-corrected p-value (p’s ≤ .001). Only the two combination conditions significantly increased the number of days to lapse, relative to placebo, when using the Bonferroni-corrected p-value (p’s < .001). Figure 3 illustrates the survival curves for latency to relapse. The survival curves for latency to lapse and for latency to relapse following a lapse were similar to the survival curves for latency to relapse. All active treatments increased the latency to relapse following the first lapse (p’s ≤ .003) with the exception of the lozenge (Wald = 6.39, p = .011, OR = .73, 95% CI = .75, .93). The same effects were obtained when analyses controlled for race, gender and site.
